What are the adverse effects and risks of giving levetiracetam (Levera) at 90 mg/kg/day to a 1‑year‑old child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Levetiracetam 90 mg/kg/day in a 1-Year-Old Child: Safety and Risks

A dose of 90 mg/kg/day of levetiracetam in a 1-year-old child significantly exceeds the typical maximum recommended dose of 60 mg/kg/day but has been used safely in pediatric populations with careful monitoring, though behavioral adverse effects become more likely at these higher doses. 1, 2

Standard Dosing Context

  • Typical pediatric dosing for levetiracetam ranges from 20-60 mg/kg/day, with acute loading doses of 40-60 mg/kg IV (maximum 2,500 mg) used for status epilepticus 1
  • Maintenance therapy in children typically uses 40-60 mg/kg/day divided into twice-daily dosing 3, 4
  • 90 mg/kg/day represents approximately 1.5 times the upper standard maintenance dose, placing it in the "high-dose" category that has been studied in refractory epilepsy 2

Safety Data at High Doses

Tolerability Evidence

  • High-dose levetiracetam studies (70-275 mg/kg/day, median 146 mg/kg/day) in 32 children aged 1-19 years showed that 44% achieved >50% seizure reduction, with only 12% experiencing adverse effects (all behavioral) 2
  • Serum levels in these high-dose studies reached 20-121 mcg/ml (median 43 mcg/ml) without serious adverse effects 2
  • No serious adverse effects were attributable to rapid IV infusion at 5 mg/kg per minute in status epilepticus studies, and levetiracetam is generally better tolerated than phenytoin or valproic acid 5, 6

Adverse Effects at Standard and High Doses

Most Common Side Effects (from FDA labeling): 7

  • Somnolence (15% in adults, 12% in children)
  • Irritability (10% in children with generalized seizures, 67% of adverse events in one pediatric study) 7, 8
  • Behavioral changes including nervousness (10% in children), personality disorder (8%), agitation (6%) 7
  • Dizziness (9% in adults, 7% in children) 7

At 90 mg/kg/day specifically:

  • Behavioral adverse effects are the primary concern, including irritability, hyperactivity, restlessness, and mood changes 2, 8
  • No correlation between serum concentration and adverse events was found in a study of 50 children receiving average doses of 43.7 mg/kg/day (range 14-100 mg/kg/day) 3
  • Serious adverse effects remain rare even at high doses, with no reports of life-threatening toxicity 2

Clinical Monitoring Recommendations

What to Watch For

  • Behavioral changes: Irritability, hyperactivity, aggression, mood swings, or personality changes should prompt dose reduction 7, 8
  • CNS effects: Somnolence, dizziness, ataxia, though these typically occur in the first 4 weeks of treatment 7
  • Seizure frequency: Paradoxical worsening occurred in 12% of children on high-dose therapy 2
  • Renal function: Dose adjustments are necessary in renal dysfunction due to predominant renal elimination 5

Laboratory Monitoring

  • Serum level monitoring is not routinely needed at 90 mg/kg/day unless assessing compliance or determining therapeutic baseline in well-controlled patients 3
  • No specific laboratory monitoring is required beyond standard clinical assessment, as levetiracetam does not cause organ toxicity at high doses 5, 2

Efficacy at This Dose

  • Children with refractory epilepsy receiving average doses of 43.7 mg/kg/day (range 14-100 mg/kg/day) showed 95% with >50% seizure reduction and 44% becoming seizure-free 3
  • At higher doses (median 146 mg/kg/day), 44% achieved >50% seizure reduction, suggesting diminishing returns above 60 mg/kg/day 2
  • 90 mg/kg/day may be appropriate for children who partially respond to lower doses but should be titrated gradually 2

Key Clinical Pitfalls

  • Abrupt discontinuation should be avoided; taper gradually if stopping 7
  • Behavioral side effects may be mistaken for worsening of underlying neurological condition rather than drug effect 8
  • Drug interactions are minimal, as levetiracetam does not interact with other anticonvulsants or common medications 4
  • Neonatal use at doses up to 60 mg/kg/day has shown safety, though a 1-year-old at 90 mg/kg/day exceeds typical neonatal dosing 9

References

Guideline

Safety and Guidelines for Co‑administration of Levetiracetam and Ibuprofen

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Adverse Effects of Levetiracetam

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Levetiracetam Safety Profile in Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Levetiracetam: safety and efficacy in neonatal seizures.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.